Aclaris Therapeutics, Inc (ACRS) - Long-Term Debt to Capital Coefficient
The biotechnology sector for the therapy of dermatological and immune pathologies is currently growing rapidly, fueling interest in Aclaris Therapeutics (ACRS) assets. Aclaris Therapeutics (ACRS) is minimizing risks by developing a portfolio of drugs for rheumatology and skin. The indicator stands at 0.01. This price chart on GURU.Markets confirms the high potential of the brand, whose small-molecule anti-inflammatory developments are trusted by industry specialists.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_ACRS_-_Aclaris-Therapeutics_-_Long-Term-Debt-to-Capital "ACRS: Aclaris Therapeutics, Inc. Long-Term Debt to Capital 07/04/2022 - 11/01/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Aclaris Therapeutics (ACRS)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Aclaris Therapeutics|ACRS - Long-Term Debt to Capital|Short-Term Debt to Capital aclaristx.com|ACRS - Company Total Debt|Debt to Net Assets Ratio Aclaris Therapeutics, Inc.|ACRS - Company Long-Term Debts|Short-Term Debt Volume Aclaris Therapeutics|Quick Liquidity Indicator aclaristx.com
- net income and valuation ratios data:
General company analysis:Aclaris Therapeutics Inc. - ACRS
This ratio determines the share of long-term liabilities within the equity structure, allowing for an assessment of financial stability and the business's degree of dependence on borrowed funds. Analyzing long-term debt-to-equity is critically important for Aclaris Therapeutics (ACRS), as colossal R&D expenditures and patent disputes require a significant liquidity buffer to mitigate clinical trial risks.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|Septerna Corp - Long-Term Debt to Capital|PVLA - Long-Term Debt to Capital|SVRA: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio rigel.com|Long-Term Debt to Equity AnaptysBio|Long-Term Debt to Equity ATXS|Long-Term Debt to Capital ENGN|Long-Term Debt to Capital rapt.com (RAPT)|Long-Term Debt to Equity Aerovate Therapeutics JBIO|Long-Term Debt to Capital Coefficient KYTX|Tiziana Life Sciences Ltd - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Cabaletta Bio Inc. CABA|Ventyx Bio (VTYX) - Long-Term Debt to Equity|THTX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio AVTX|ELDN: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio AGEN (Agenus Inc.)|Long-Term Loans to Capital Ratio CLYM|Long-Term Debt to Capital ZURA (Zura Bio Limited)|Long-Term Debt to Capital Coefficient ATYR|Adagene Corp - Long-Term Debt to Capital|Long-Term Liabilities to Capital ImageneBio Inc|shattucklabs.com (STTK) - Long-Term Debt to Equity|Equillium - Long-Term Debt to Capital Coefficient|CNTB (Connect Biopharma Holdings) - Long-Term Debt to Capital|Long-Term Debt to Capital Immunic Inc|Long-Term Debt to Equity Atara Biotherapeutics (ATRA)|IFRX: Long-Term Liabilities to Equity|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|Adicet Bio Inc. (ACET) - Long-Term Liabilities to Capital|CELU: Long-Term Debt to Equity Ratio|INMB - Long-Term Debt to Capital|BRNS (Barinthus Biotherapeutics) - Long-Term Debt to Equity Ratio|KZR: Long-Term Loans to Capital Ratio|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|Akari Therapeutics PLC (AKTX) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital ENLV|Long-Term Debt to Equity Ratio q32bio.com QTTB|Long-Term Debt to Equity GeoVax Labs, Inc. GOVX|Ratio of Long-Term Indebtedness to Capital edesabiotech.com (EDSA)|iBio - Long-Term Debt to Capital|CARM - Long-Term Debt to Capital|XTLB: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Bolt Biotherapeutics, Inc.|Long-Term Debt to Equity HCW Biologics, Inc.|APVO: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity AIM ImmunoTech (AIM)|Ratio of Long-Term Indebtedness to Capital aditxt.com|Long-Term Debt to Equity GRI Bio Corp GRI|XRTX (XORTX Corp) - Long-Term Liabilities to Equity|Vyome Holdings Inc - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient REVB (revbiosciences.com)|INDP: Long-Term Debt to Capital|Scinai Immunotherapeutics Ltd (SCNI) - Long-Term Debt to Capital|Long-Term Debt to Equity CalciMedica Inc|AFMD: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Allakos Inc. (ALLK)|Long-Term Debt to Equity Ratio hookipapharma.com HOOK|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Debt to Capital iTeos Therapeutics Inc ITOS|OCEA: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient TCBP (TC BioPharm Ltd)|THRD: Long-Term Debt to Capital